Table 4.

Results of univariate and multivariate analyses of graft and patient factors influencing aGVHD grades II to IV and cGVHD

Variable	Univariate analysis (includes only significant variables)			Multivariate analysis (includes only significant variables)			Favorable in multivariate analysis
	Hazard ratio	95% CI	P	Hazard ratio	95% CI	P
aGVHD grades II-IV*
Date of transplantation
After January 1, 2001	2.07	0.99-4.35	.05
Before January 1, 2001	1.000
ABO match
Mismatched	1.88	1.14-3.08	.01	1.92	1.17-3.15	< .01	ABO matched
Matched	1.00			1.00
cGVHD†
CD34, × 105/kg
More than 2.1	0.54	0.29-1.02	.06	0.43	0.22-0.82	.01	CD34 > 2.1
2.1 or less	1.00			1.00
Recipient ethnicity
Other	2.50	1.19-5.24	.02	3.40	1.6-7.45	.002	White patient
White	1.00			1.00
ABO match
Mismatched	2.09	1.12-3.90	.02	2.36	1.3-4.45	.008	ABO matched
Matched	1.00			1.00

^*Grades II-IV aGVHD: Variables not found to be statistically significant in univariate analysis include performance status (< 80, ≥ 80), age (> 2 years, < 2 years), recipient sex, unit sex, sex matching (recipient/unit), cryopreserved cell dose × 10⁷/kg (> 9.7, ≤ 9.7), reinfused cell dose × 10⁷/kg (> 7.6, ≤ 7.6), reinfused CD34 × 10⁵/kg (> 2.1, ≤ 2.1), reinfused CFUs × 10⁴/kg (> 5.7, ≤ 5.7), reinfused CD3 × 10⁶/kg (> 14.2, ≤ 14.2), recipient ethnicity, unit ethnicity, ethnicity matching (recipient/unit), HLA match (5/6 and 6/6, 3/6 and 4/6), recipient CMV serostatus, and recipient weight (< 12 kg, ≥ 12 kg).

^†cGVHD: Variables not found to be statistically significant in univariate analysis include performance status (< 80, ≥ 80), age (> 2 years, < 2 years), recipient sex, unit sex, cryopreserved cell dose × 10⁷/kg (> 9.7, ≤ 9.7), reinfused cell dose × 10⁷/kg (> 7.6, ≤ 7.6), reinfused CFUs × 10⁴/kg (> 5.7, ≤ 5.7), reinfused CD3 × 10⁶/kg (> 14.2, ≤ 14.2), date of transplantation (after 1/1/2001, before 1/1/2001), unit ethnicity, ethnicity matching (recipient/unit), HLA match (5/6 and 6/6, 3/6 and 4/6), recipient CMV serostatus, and recipient weight (< 12 kg, ≥ 12 kg).